Stocks · News reference
10x Genomics won a $4.8 million patent infringement lawsuit against Qiagen subsidiary Parse Biosciences, prompting plans for an injunction.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Bruker Energy & Supercon Technologies (BEST), a segment of Bruker Corporation (NASDAQ:BRKR), and Luvata Materials & Solutions, a Business Unit of Luvata Group (LUVATA) today announced a strategic collaboration
The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with 34% market share, while Asia Pacific is the fastest-growing region at 15.5% CAGR. Consumables dominate with 68% market share, and protein multiplex assays hold 42%. Growth is driven by precision medicine, companion diagnostics, and laboratory automation.
10x Genomics secured a favorable jury verdict against Parse Biosciences (a Qiagen subsidiary), winning $4.8M in damages for willful patent infringement on three single-cell analysis patents. The jury upheld all three patents' validity. 10x Genomics plans to seek enhanced damages, attorney fees, and a permanent U.S. injunction in post-trial proceedings. Despite the legal win, TXG shares fell over 5% following the announcement.
Jury finds Parse willfully infringed Scale Biosciences' patents and rejects Parse's invalidity challengePLEASANTON, Calif., Aug. 28, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), the life science